Evaluation of the immunomodulatory response of Sevoflurane versus Propofol in the intraoperative of obese patients (obesita): study protocol for a randomized clinical trial

Rede D'Or Sao Luiz S.A.0 个研究点开始时间: 2018年8月30日最近更新: 2023年5月29日

研究概览

暂无简介。

•Age range 18 to 59 years; body mass index greater than or equal to 35 kilograms per square meter; signature of the free and informed consent form.

•Patients with insulin; anti-inflammatory and / or immunosuppressive therapies; diagnosis of malignant disease; chronic kidney disease, with KDOQI greater than 3; chronic liver disease, with total serum protein less than 3 grams per deciliter and total bilirubin greater than 5 milligrams per deciliter; heart disease, with NYHA III or IV; obesity caused by endocrine disorder; patients with psychiatric illness that may interfere with the capacity for formal consent and compliance; persistent smoking associated with significant obstructive or restrictive lung disease, with vital capacity or forced expiratory volume in one second less than 50% of predicted value; alcohol dependence; pre-existing coagulation disorders; evident pulmonary or systemic infection, with clinically defined or increased C reactive protein above 5 milligrams per ml, leukocytosis greater than 10,000, or body temperature greater than 37 Celsius; presence of autoimmune diseases; participated in another randomized clinical trial in the last year.

发起方

Rede D'Or Sao Luiz S.A.